Navigation Links
Celsion Announces CFO Departure
Date:1/8/2010

COLUMBIA, Md., Jan. 8 /PRNewswire-FirstCall/ -- CELSION CORPORATION (Nasdaq: CLSN) today announced the departure of Sean F. Moran, Chief Financial Officer, effective January 8, 2010. Mr. Moran leaves Celsion to pursue other professional opportunities. Timothy J. Tumminello, CPA, the Company's controller, will assume the position of Interim Chief Accounting Officer and the responsibilities of the Company's financial officer. Celsion has retained CTPartners to lead its search for a new CFO.

"Celsion has great respect for Sean's work and expertise," commented Michael H. Tardugno, Celsion's President and CEO. "We wish him well in his future endeavors."

About Celsion

Celsion is dedicated to the development and commercialization of innovative oncology drugs including tumor-targeting treatments using focused heat energy in combination with heat-activated drug delivery systems. Celsion has licensed ThermoDox® to Yakult-Honsha for the Japanese market and has a partnership agreement with Phillips Medical to jointly develop its heat activated liposomal technology in combination with high intensity focused ultrasound to treat difficult cancers. Celsion has research, license, or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, Cleveland Clinic, and the North Shore Long Island Jewish Health System.

For more information on Celsion, visit our website: http://www.celsion.com

Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.


    Contact:
    Marcy Nanus
    The Trout Group, LLC
    646-378-2927
    mnanus@troutgroup.com

SOURCE Celsion Corporation

RELATED LINKS
http://www.celsion.com

'/>"/>

SOURCE Celsion Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Anesiva Announces Merger With Arcion Therapeutics Will Not be Completed
2. Warner Chilcott Announces Early Tender Results and Receipt of Consents from a Majority of Holders of its 8-3/4% Senior Subordinated Notes due 2015
3. Vion Pharmaceuticals Announces FDA Conclusion
4. Connectyx Announces MedFlash Sales Partnership with National Recreational Vehicle Club
5. Arigene Co., Ltd. Announces Termination of Tender Offer To Purchase and Return of Validly Tendered Shares of Common Stock of Trimeris, Inc.
6. Vermillion Announces $43.05 Million Private Placement of Common Stock
7. ViVre Medical Announces $6,000,000 Gift
8. Soligenix Announces Publication of Positive Pre-Clinical Results with RiVax(TM), Its Vaccine Against Ricin Toxin
9. Maxygen, Inc. Announces Preliminary Results of Dutch Auction Tender Offer
10. Boston Scientific Announces Settlement of DOJ Investigation Relating to Post-Market Surveys Conducted By Guidant
11. Raptor Pharmaceutical Corp. Announces Closing of $7.5 Million Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 20, 2017  Cogentix Medical, Inc. (NASDAQ: CGNT), ... the Urology, Uro/Gyn and Gynecology markets with innovative ... has joined the Company as Senior Vice President, ... position, Mr. Keswani will report directly to ... "Our organization is delighted that Ash has joined ...
(Date:4/20/2017)... Research and Markets has announced the addition of the "Global ... and Increasing Usage of Complex Biologics during the Forecast Period" ... The ... Billion in 2015 to around USD 26 Billion by 2020. ... Rapidly Expanding Injectables Market and Increasing Usage of Complex Biologics during ...
(Date:4/20/2017)... 20, 2017 Eyevensys, a private ... non-viral gene expression technology that enables the safe, local, ... address a wide range of ophthalmic diseases, announces it ... products Regulatory Agency (MHRA) to advance its technology into ... ...
Breaking Medicine Technology:
(Date:4/28/2017)... R.I. (PRWEB) , ... April 28, 2017 , ... Getting enough sleep affects much more ... Foundation (NSF), going just 19 hours without sleep can compromise motor reaction time, which can ... Week, and Amica Insurance is sharing the following tips from the NSF to help you ...
(Date:4/28/2017)... ... April 28, 2017 , ... Datta Endoscopic Back Surgery and ... revolutionary endoscopic practice under Dr. Datta. Patel is a Board Certified Anesthesiologist, with ... revolutionary eDiscSculpt Technique created and used by Datta Endoscopic is unlike traditional back ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... People are ... older people. “Wearing a hearing aid doesn’t have the stigma it had when great-grandpa ... Hearing Associates of Greater Boston, in a NALA North American Speaker Series ...
(Date:4/28/2017)... ... April 28, 2017 , ... Intellitec ... Brooke Grove Foundation implement a Microsoft Dynamics GP solution that integrates to their ... expert that specializes in long-term care, Brooke Grove now has the capability to ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... Christie ... today announced an alliance with B. Braun Medical Inc. , a leader in ... in patient care with as many as 90 percent of hospital patients receiving a ...
Breaking Medicine News(10 mins):